UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4252) 4252
covid-19 (4248) 4248
sars-cov-2 (4229) 4229
pandemics (3775) 3775
science & technology (3714) 3714
life sciences & biomedicine (3481) 3481
betacoronavirus (2283) 2283
coronaviruses (2223) 2223
pneumonia, viral - epidemiology (1498) 1498
coronavirus infections - epidemiology (1494) 1494
severe acute respiratory syndrome coronavirus 2 (1338) 1338
coronavirus infections - drug therapy (1317) 1317
pneumonia, viral - drug therapy (1259) 1259
coronavirus infections - virology (1092) 1092
pneumonia, viral - virology (1088) 1088
female (1048) 1048
male (1022) 1022
betacoronavirus - drug effects (859) 859
middle aged (733) 733
coronavirus infections - complications (728) 728
pneumonia, viral - complications (727) 727
coronavirus infections - prevention & control (719) 719
pandemics - prevention & control (704) 704
pneumonia, viral - prevention & control (683) 683
viral diseases (668) 668
adult (634) 634
infections (630) 630
coronavirus infections - diagnosis (619) 619
severe acute respiratory syndrome (619) 619
aged (595) 595
pneumonia, viral - diagnosis (583) 583
coronavirus infections - therapy (564) 564
coronavirus infections - immunology (561) 561
pneumonia, viral - therapy (558) 558
betacoronavirus - pathogenicity (556) 556
epidemics (547) 547
pneumonia, viral - immunology (537) 537
patients (529) 529
health aspects (519) 519
coronavirus (501) 501
disease transmission (501) 501
betacoronavirus - isolation & purification (494) 494
risk factors (479) 479
viruses (475) 475
general & internal medicine (472) 472
mortality (455) 455
antiviral agents - therapeutic use (452) 452
animals (448) 448
infectious diseases (433) 433
coronavirus infections (417) 417
medicine, general & internal (414) 414
betacoronavirus - immunology (412) 412
public health (408) 408
pneumonia, viral (396) 396
abridged index medicus (375) 375
respiratory diseases (372) 372
review (369) 369
betacoronavirus - physiology (346) 346
immunology (344) 344
angiotensin-converting enzyme 2 (339) 339
pneumonia (331) 331
pharmacology & pharmacy (325) 325
coronavirus infections - transmission (323) 323
pneumonia, viral - transmission (321) 321
vaccines (321) 321
coronavirus infections - mortality (315) 315
medicine, research & experimental (314) 314
pneumonia, viral - mortality (314) 314
research & experimental medicine (313) 313
antiviral agents - pharmacology (308) 308
covid‐19 (306) 306
inflammation (300) 300
medical research (298) 298
clinical trials (296) 296
coronavirus infections - pathology (293) 293
pneumonia, viral - pathology (292) 292
retrospective studies (285) 285
coronavirus infections - physiopathology (283) 283
pneumonia, viral - physiopathology (283) 283
treatment outcome (279) 279
public, environmental & occupational health (272) 272
betacoronavirus - genetics (268) 268
comorbidity (267) 267
biochemistry & molecular biology (259) 259
proteins (248) 248
severity of illness index (242) 242
peptidyl-dipeptidase a - metabolism (237) 237
cardiovascular system & cardiology (231) 231
epidemiology (227) 227
aged, 80 and over (221) 221
cytokines (221) 221
science & technology - other topics (217) 217
young adult (214) 214
viral infections (210) 210
hospitals (208) 208
antiviral agents (207) 207
hypertension (198) 198
cell biology (197) 197
adolescent (196) 196
china (195) 195
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4300) 4300
Chinese (30) 30
Spanish (20) 20
Portuguese (16) 16
French (15) 15
Italian (7) 7
German (5) 5
Russian (4) 4
Hungarian (3) 3
Norwegian (2) 2
Swedish (2) 2
Danish (1) 1
Dutch (1) 1
Japanese (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature reviews. Drug discovery, ISSN 1474-1776, 03/2020, Volume 19, Issue 3, pp. 149 - 150
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Science & Technology | Betacoronavirus - pathogenicity | Recombinant Proteins - therapeutic use | Interferon-alpha - pharmacology | Alanine - therapeutic use | Hepatitis C - drug therapy | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Polyethylene Glycols - therapeutic use | COVID-19 | Alanine - analogs & derivatives | Protease Inhibitors - pharmacology | SARS-CoV-2 | SARS Virus - genetics | Nucleosides - pharmacology | Spike Glycoprotein, Coronavirus - drug effects | Influenza, Human - drug therapy | Protease Inhibitors - therapeutic use | Polyethylene Glycols - pharmacology | Nucleosides - therapeutic use | Antiviral Agents - therapeutic use | Betacoronavirus - drug effects | Interferon-alpha - therapeutic use | Middle East Respiratory Syndrome Coronavirus - drug effects | SARS Virus - drug effects | Drug Repositioning | Recombinant Proteins - pharmacology | Adenosine Monophosphate - therapeutic use | SARS Virus - pathogenicity | Middle East Respiratory Syndrome Coronavirus - pathogenicity | Middle East Respiratory Syndrome Coronavirus - genetics | Adenosine Monophosphate - analogs & derivatives | Hepatitis B - drug therapy | HIV Infections - drug therapy | Betacoronavirus - genetics | Antiviral agents | Pharmacology, Experimental | Physiological aspects | Drug targeting | Genetic aspects | Research | Coronaviruses | Clinical trials | Index Medicus
Journal Article
by Gordon, David E and Jang, Gwendolyn M and Bouhaddou, Mehdi and Xu, Jiewei and White, Kris M and O’Meara, Matthew J and Rezelj, Veronica V and Swaney, Danielle L and Tummino, Tia A and Foussard, Helene and Batra, Jyoti and Haas, Kelsey and Modak, Maya and Kim, Minkyu and Braberg, Hannes and Fabius, Jacqueline M and Eckhardt, Manon and Soucheray, Margaret and Cakir, Merve and McGregor, Michael J and Li, Qiongyu and Vallet, Thomas and Mac Kain, Alice and Miorin, Lisa and Moreno, Elena and Zhou, Yuan and Peng, Shiming and Shi, Ying and Zhang, Ziyang and Shen, Wenqi and Melnyk, James E and Chorba, John S and Lou, Kevin and Dai, Shizhong A and Barrio-Hernandez, Inigo and Lyu, Jiankun and Mathy, Christopher J. P and Perica, Tina and Pilla, Kala Bharath and Ganesan, Sai J and Saltzberg, Daniel J and Rakesh, Ramachandran and Liu, Xi and Rosenthal, Sara B and Calviello, Lorenzo and Lin, Yizhu and Huang, Xi-Ping and Liu, YongFeng and Bohn, Markus and Safari, Maliheh and Ugur, Fatima S and Koh, Cassandra and Savar, Nastaran Sadat and Tran, Quang Dinh and Fletcher, Sabrina J and O’Neal, Michael C and Chang, Jason C. J and Broadhurst, David J and Klippsten, Saker and Sharp, Phillip P and Wenzell, Nicole A and Kuzuoglu-Ozturk, Duygu and Wang, Hao-Yuan and Trenker, Raphael and Young, Janet M and Cavero, Devin A and Hiatt, Joseph and Roth, Theodore L and Rathore, Ujjwal and Subramanian, Advait and Noack, Julia and Hubert, Mathieu and Stroud, Robert M and Frankel, Alan D and Rosenberg, Oren S and Verba, Kliment A and Agard, David A and Ott, Melanie and Emerman, Michael and Jura, Natalia and von Zastrow, Mark and Verdin, Eric and Ashworth, Alan and Schwartz, Olivier and d’Enfert, Christophe and Mukherjee, Shaeri and Jacobson, Matt and Malik, Harmit S and Craik, Charles S and Floor, Stephen N and Fraser, James S and Gross, John D and Roth, Bryan L and Ruggero, Davide and Taunton, Jack and Beltrao, Pedro and García-Sastre, Adolfo and Shokat, Kevan M and Shoichet, Brian K and Krogan, Nevan J
Nature (London), ISSN 0028-0836, 07/2020, Volume 583, Issue 7816, pp. 459 - 468
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Betacoronavirus - pathogenicity | Pandemics | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Host-Pathogen Interactions - drug effects | Molecular Targeted Therapy | Viral Proteins - metabolism | Protein Interaction Maps | COVID-19 | Pneumonia, Viral - metabolism | SARS-CoV-2 | Antiviral Agents - classification | Coronavirus Infections - metabolism | Mass Spectrometry | Cloning, Molecular | HEK293 Cells | Protein Domains | Drug Evaluation, Preclinical | Receptors, sigma - metabolism | Vero Cells | Antiviral Agents - pharmacology | Chlorocebus aethiops | Betacoronavirus - drug effects | Viral Proteins - genetics | SKP Cullin F-Box Protein Ligases - metabolism | Drug Repositioning | Betacoronavirus - metabolism | Immunity, Innate | Coronavirus Infections - immunology | Pneumonia, Viral - immunology | Protein Interaction Mapping | Animals | Coronavirus Infections - virology | Protein Binding | Protein Biosynthesis - drug effects | Betacoronavirus - genetics | Pneumonia, Viral - virology | Protein research | Drug targeting | Genetic aspects | Coronaviruses | Research | Health aspects | Methods | Interactomes | Drugs | Regulators | Laboratories | Protein purification | Viral diseases | Clinical trials | Infections | Genomes | mRNA | Vaccines | Middle East respiratory syndrome | Proteins | Antiviral activity | Antiviral agents | Enzymes | Severe acute respiratory syndrome | Cloning | Mass spectroscopy | RNA polymerase | Gene expression | Severe acute respiratory syndrome coronavirus 2 | Respiratory diseases | Fatalities | Scientific imaging | Protein interaction | Mass spectrometry | Index Medicus
Journal Article
Journal of allergy and clinical immunology, ISSN 0091-6749, 10/2020, Volume 146, Issue 4, pp. 786 - 789
COVID-19 | adverse drug reactions | SARS-CoV-2 | drug allergy | coronavirus | Acute respiratory syndrome | remdesivir | drug hypersensitivity | Allergy | Immunology | Life Sciences & Biomedicine | Science & Technology | Betacoronavirus - pathogenicity | Interleukin 1 Receptor Antagonist Protein - administration & dosage | Pandemics | Alanine - adverse effects | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Pyrazines - administration & dosage | Drug Hypersensitivity - drug therapy | Adrenal Cortex Hormones - therapeutic use | Indoles - administration & dosage | Infliximab - administration & dosage | Betacoronavirus - immunology | Alanine - analogs & derivatives | Infliximab - adverse effects | Alanine - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Amides - adverse effects | Drug Hypersensitivity - diagnosis | Pyrazoles - adverse effects | Drug Hypersensitivity - etiology | Severity of Illness Index | Antibodies, Monoclonal, Humanized - adverse effects | Cytokine Release Syndrome - immunology | Cytokine Release Syndrome - virology | Immunity, Innate - drug effects | Cytokine Release Syndrome - prevention & control | Betacoronavirus - drug effects | Immunologic Factors - administration & dosage | Antiviral Agents - administration & dosage | Coronavirus Infections - immunology | Pneumonia, Viral - immunology | Adenosine Monophosphate - adverse effects | Pyrazoles - administration & dosage | Indoles - adverse effects | Coronavirus Infections - virology | Drug Hypersensitivity - immunology | Adenosine Monophosphate - administration & dosage | Adenosine Monophosphate - analogs & derivatives | Antiviral Agents - adverse effects | Pyrazines - adverse effects | Interleukin 1 Receptor Antagonist Protein - adverse effects | Immunologic Factors - adverse effects | Amides - administration & dosage | Pneumonia, Viral - virology | Index Medicus | Abridged Index Medicus | Covid-19
Journal Article
Journal of medical virology, ISSN 0146-6615, 07/2020, Volume 92, Issue 7, pp. 726 - 730
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) | coronavirus disease 2019 (COVID‐19) | renin‐angiotensin system (RAS) | acute respiratory distress syndrome (ARDS) | angiotensin‐converting enzyme 2 (ACE2) | Life Sciences & Biomedicine | Science & Technology | Virology | Betacoronavirus - pathogenicity | Pandemics | Prognosis | Age Factors | Receptors, Virus - metabolism | Cardiovascular Diseases - drug therapy | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Angiotensin I - therapeutic use | Receptors, Virus - genetics | Cardiovascular Diseases - genetics | COVID-19 | Peptidyl-Dipeptidase A - genetics | Cardiovascular Diseases - complications | Receptor, Angiotensin, Type 1 - genetics | SARS-CoV-2 | Pneumonia, Viral - genetics | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Coronavirus Infections - epidemiology | Pneumonia, Viral - epidemiology | Pneumonia, Viral - complications | Peptidyl-Dipeptidase A - metabolism | Cardiovascular Diseases - epidemiology | Coronavirus Infections - complications | Spike Glycoprotein, Coronavirus - genetics | Spike Glycoprotein, Coronavirus - metabolism | Signal Transduction | Antiviral Agents - therapeutic use | Betacoronavirus - drug effects | Gene Expression Regulation | Coronavirus Infections - genetics | Angiotensin-Converting Enzyme 2 | Host-Pathogen Interactions - genetics | Receptor, Angiotensin, Type 1 - metabolism | Sex Factors | Peptide Fragments - therapeutic use | Drugs | Health services | Epithelial cells | Viral diseases | Homeostasis | Cardiovascular disease | Vaccines | Drug development | Risk factors | Proteins | Renin | Alveoli | Angiotensin II | Hypertension | Enzymes | Spike protein | Severe acute respiratory syndrome | Diabetes mellitus | Health risks | Coronaviruses | Risk analysis | Patients | Conversion | Respiratory distress syndrome | Lungs | Angiotensin | Diabetes | Cardiovascular diseases | Index Medicus | Reviews | Review
Journal Article
Nature (London), ISSN 0028-0836, 10/2020, Volume 586, Issue 7827, pp. 113 - 119
Journal Article
Nature reviews. Immunology, ISSN 1474-1733, 10/2020, Volume 20, Issue 10, pp. 633 - 643
Life Sciences & Biomedicine | Immunology | Science & Technology | Betacoronavirus - pathogenicity | SARS Virus - immunology | Antibodies, Neutralizing - administration & dosage | Pandemics | Severe Acute Respiratory Syndrome - virology | Antibodies, Monoclonal - biosynthesis | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Antibodies, Monoclonal - adverse effects | Severe Acute Respiratory Syndrome - immunology | Host-Pathogen Interactions - drug effects | Receptors, IgG - antagonists & inhibitors | Virus Internalization - drug effects | Host-Pathogen Interactions - immunology | Betacoronavirus - immunology | COVID-19 | Leukocytes - immunology | Receptors, IgG - genetics | SARS-CoV-2 | Dengue - drug therapy | Dengue Virus - immunology | Dengue Virus - pathogenicity | Antibodies, Neutralizing - adverse effects | Antibody-Dependent Enhancement - drug effects | Dengue - immunology | Antibodies, Viral - administration & dosage | Antibodies, Viral - biosynthesis | Antibodies, Viral - adverse effects | Dengue Virus - drug effects | Signal Transduction | Betacoronavirus - drug effects | Gene Expression Regulation | SARS Virus - drug effects | Dengue - virology | Receptors, IgG - immunology | Severe Acute Respiratory Syndrome - drug therapy | Coronavirus Infections - immunology | Pneumonia, Viral - immunology | SARS Virus - pathogenicity | Coronavirus Infections - virology | Antibodies, Monoclonal - administration & dosage | Antibodies, Neutralizing - biosynthesis | Leukocytes - virology | Leukocytes - drug effects | Pneumonia, Viral - virology | Infection | Virus diseases | Fc receptors | Antiviral agents | Immune response | Phosphoproteins | Analysis | Dengue viruses | Immunoglobulin G | B cells | Health aspects | Severe acute respiratory syndrome coronavirus 2 | Pathogenesis | Dengue fever | Dengue | Antibodies | Infections | Viral infections | Index Medicus
Journal Article
European journal of cancer (1990), ISSN 0959-8049, 09/2020, Volume 136, pp. 1 - 3
COVID-19 | Anticancer drugs | Antiviral interactions | Drug interactions | Drug-induced long QT syndrome | Life Sciences & Biomedicine | Oncology | Science & Technology | Pandemics | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Cytochrome P-450 Enzyme System - metabolism | Long QT Syndrome - chemically induced | Pyrazines - metabolism | Hydroxychloroquine - adverse effects | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents, Hormonal - adverse effects | Neoplasms - complications | SARS-CoV-2 | Drug Interactions | Ritonavir - adverse effects | Immunosuppression - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia, Viral - complications | Amides - adverse effects | Kidney Diseases - chemically induced | Betacoronavirus | Coronavirus Infections - complications | Amides - metabolism | Chemical and Drug Induced Liver Injury - etiology | Antibodies, Monoclonal, Humanized - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - adverse effects | Proteasome Inhibitors - adverse effects | Neoplasms - drug therapy | Antineoplastic Agents, Immunological - adverse effects | Antiviral Agents - adverse effects | Pyrazines - adverse effects | Drug Combinations | Histone Deacetylase Inhibitors - adverse effects | Lopinavir - adverse effects | Antimitotic agents | Medical research | Antiviral agents | Cancer patients | Medicine, Experimental | Drug therapy | Antineoplastic agents | Antitumor agents | Index Medicus | Life Sciences | Microbiology and Parasitology | Virology | Cancer
Journal Article
Nature reviews. Immunology, ISSN 1474-1733, 09/2020, Volume 20, Issue 9, pp. 515 - 516
Life Sciences & Biomedicine | Immunology | Science & Technology | Betacoronavirus - pathogenicity | Glycine - therapeutic use | Superoxide Dismutase - genetics | Reactive Oxygen Species - metabolism | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Host-Pathogen Interactions - drug effects | Betacoronavirus - immunology | COVID-19 | SARS-CoV-2 | Extracellular Traps - immunology | Extracellular Traps - drug effects | Cytokines - genetics | Proteinase Inhibitory Proteins, Secretory - therapeutic use | Neutrophils - drug effects | Coronavirus Infections - immunology | Neutrophils - virology | Reactive Oxygen Species - antagonists & inhibitors | Coronavirus Infections - virology | Lung - drug effects | Oxidative Stress - drug effects | Glycine - analogs & derivatives | Pandemics | Extracellular Traps - metabolism | NF-kappa B - immunology | NF-E2-Related Factor 2 - immunology | Lung - virology | Lymphocytes - immunology | Lymphocytes - virology | Reactive Oxygen Species - immunology | NF-E2-Related Factor 2 - genetics | Acetylcysteine - therapeutic use | Drug Therapy, Combination | Cytokines - immunology | Severity of Illness Index | Lung - pathology | Immunity, Innate - drug effects | Betacoronavirus - drug effects | Gene Expression Regulation | Neutrophils - immunology | Pneumonia, Viral - immunology | Superoxide Dismutase - immunology | Antioxidants - therapeutic use | NF-kappa B - genetics | Sulfonamides - therapeutic use | Lymphocytes - drug effects | Pneumonia, Viral - virology | Lung - immunology | Oxidative stress | Reactive oxygen species | Neutrophils | Erythrocytes | Leukocytes (neutrophilic) | Coronaviruses | Thrombosis | Index Medicus | Life Sciences
Journal Article
Nature (London), ISSN 0028-0836, 07/2020, Volume 583, Issue 7816, pp. 469 - 472
Journal Article